Group 1: Internal Control and Risk Management - The company has completed part of the internal control rectification, with ongoing efforts for the remaining issues [3][12] - The company will apply to the stock exchange for the removal of the ST (other risk warning) status once internal control deficiencies are rectified and effectively operational [3][12][22] - The company has established a rectification leadership group and formulated a rectification implementation plan [12][30] Group 2: Financial Performance and Debt Management - The company's debt ratio is currently at 95%, with measures being taken to optimize bank financing products and reduce financial costs [4][28] - The company is focusing on cash flow-oriented operations and prioritizing high-profit, quick-recovery projects to lower capital occupation costs [6][28] - The company expects to achieve a historical high in new contract amounts this year, potentially reaching 41 billion [14][67] Group 3: Project Execution and Orders - Major projects such as the Wuhan Southern Waste-to-Energy Plant expansion and the Laos Southern Clean Energy Project are currently in execution [3][4] - The company is actively tracking and promoting project progress based on specific conditions and risk situations [3][19] - The company has received partial prepayments for the Laos Clean Energy Project, with ongoing preparations for project initiation [21][83] Group 4: Shareholder and Market Engagement - As of September 12, the number of shareholders is 51,037, with no significant changes reported since June 30 [5][60] - The company is open to engaging with various investors to enhance its operational quality and market presence [4][78] - The company plans to disclose the top ten shareholders in the upcoming quarterly report [5][28]

| | 海南葫芦娃药业集团股份有限公司2025 年半年度报告摘要 | | | | | --- | --- | --- | --- | --- | | 公司代码：605199 | 公司简称：ST 葫芦娃 | | | | | | 海南葫芦娃药业集团股份有限公司 | | | | | | 海南葫芦娃药业集团股份有限公司2025 年半年度报告摘要 | | | | | | 第一节 | 重要提示 | | | | 展规划，投资者应当到 | www.sse.com.cn | 网站仔细阅读半年度报告全文。 | | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | | 报告期内，公司不进行利润分配或公积金转增股本 | | | | | | | 第二节 | 公司基本情况 | | | | | 公司股票简况 | | | | | 股票种类 | 股票上市交易所 | 股票简称 | 股票代码 | 变更前 | | 股票简称 | | | | | | A股 | 上海证券交易所 ST葫芦娃 | | 605199 | 葫芦娃 | | 联系人和联系方式 | | 董事会秘书 | | 证券事务代表 | | 姓 ...

证券代码：835670 证券简称：数字人 公告编号：2025-056 山东数字人科技股份有限公司 一、披露股票可能被实施退市风险警示的风险提示公告的原因 于公司内部控制审计报告》议案。公司于 2025 年 4 月 29 日在北京证券交易所 官网 （http://www.bse.cn）上披露了《内部控制审计报告》（公告编号： 公司 2024 年度财务报告内部控制被出具否定意见的审计报告，触及《北京 证券交易所股票上市规则》10.4.2 条"（六）首个会计年度财务报告内部控制 被出具无法表示意见或否定意见的审计报告，或者未按照规定披露财务报告内 部控制审计报告"应当立即披露股票可能被实施退市风险警示的风险提示公告 情形。敬请广大投资者注意投资风险。 二、公司股票可能被实施退市风险警示的风险提示 根据《北京证券交易所股票上市规则》第 10.4.2 条第(六)项规定,上市公 司出现"首个会计年度财务报告内部控制被出具无法表示意见或否定意见的审 计报告，或者未按照规定披露财务报告内部控制审计报告"的情形，上市公司 应当立即披露股票交易可能被实施退市风险警示的风险提示公告，并且应当至 少每月披露一次进展情况及风险提示公告 ...

Core Viewpoint - Tianye Innovation Co., Ltd. faces potential delisting risk due to a negative audit opinion on its internal control for the first accounting year, as per the Beijing Stock Exchange regulations [1][2][3] Group 1: Reasons for Potential Delisting Risk Warning - The company received a negative audit report from Zhongxinghua Accounting Firm regarding its internal control for the financial report as of December 31, 2024, triggering the delisting risk warning clause [2][3] - If the company continues to receive negative opinions on its internal control for two consecutive accounting years, it may face further delisting actions from the Beijing Stock Exchange [3] Group 2: Internal Control Rectification Progress - The company is actively conducting internal control self-inspection and rectification, acknowledging major deficiencies in compliance awareness among management and the inadequacy of existing internal control systems [3][4] - Measures taken include revising management systems, enhancing supervision of key control points, and increasing compliance awareness among employees through meetings [4] - The company is also focusing on improving employee competency by recruiting talent in finance, internal audit, and sales departments, and restructuring the sales department for better resource allocation [4][5] Group 3: Specific Actions Taken - The company has engaged intermediaries to assist in reviewing internal control systems and has communicated with partners regarding investment obligations [5] - A trial run of the procurement approval process has been initiated to address identified risks in agricultural product pricing, along with the establishment of a standardized return and exchange process [5] - The company has committed to ongoing improvements in its internal control system, recognizing it as a long-term and complex process that requires continuous enhancement [4][6] Group 4: Disclosure of Risk Warning Announcements - The company has disclosed risk warning announcements on its internal control rectification progress on May 30, June 30, and July 31, 2025, on the Beijing Stock Exchange website [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●中通国脉通信股份有限公司（以下简称"公司"）2022年度内部控制审计报告被致同会计师事务所（特 殊普通合伙）出具了否定意见，根据《上海证券交易所股票上市规则（2025年4月修订）》9.8.1条第 （三）项的规定，公司股票于2023年5月4日被上海证券交易所实施其他风险警示。 ●根据《上海证券交易所股票上市规则（2025年4月修订）》第9.8.5条："上市公司股票因9.8.1条第 （二）项至第（五）项规定情形被实施其他风险警示的，在被实施其他风险警示期间，公司应当至少每 月发布1次提示性公告，分阶段披露涉及事项的解决进展情况"。公司将每月披露一次其他风险警示相关 事项的进展情况，提示相关风险。 一、公司被实施其他风险警示的相关情况 2025年7月30日 二、公司被实施其他风险警示后所采取的措施 针对内部控制报告中涉及的相关问题，公司高度重视，经董事会研究决定，公司成立了内部控制整改小 组（以下简称"整改小组"），根 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603559 证券简称：ST通脉（维权） 公告编号：2025-062 中通国脉通信股份有限公司 关于公司股票继续被实施其他风险警示相关事项的进展公告 公司在2024年期间进行了重整，于2024年12月30日，被长春市中级人民法院裁定确认公司《重整计划》 执行完毕，并终结公司重整程序，公司按照相关规定未披露2024年度财务报告内部控制审计报告。根据 《上海证券交易所股票上市规则（2025年4月修订）》9.8.1条第（三）项"最近一个会计年度财务报告内 部控制被出具无法表示意见或否定意见的审计报告，或未按照规定披露财务报告内部控制审计报告"的 规定，公司股票于2025年7月4日被上海证券交易所继续实施其他风险警示。 二、公司被实施其他风险警示后所采取的措施 针对内部控制报告中涉及的相关问题，公司高度重视，经董事会研究决定，公司成立了内部控制整改小 组（以下简称"整改小组"），根据整改小组的要求，公司梳理了内部控制和经营管理思路，目前，已经 依据经营管理理念对组织架构、资金活动、采购业务、资产管理四个方面完成梳理，确定内部控制管理 目标。同时，公司借助专业 ...

Core Viewpoint - The law firm Zhejiang Tiance (Shenzhen) has conducted a special legal review for Shenzhen Zengtong Electronics Co., Ltd. regarding the inquiry letter about the 2024 annual report, confirming that the company has rectified its internal control deficiencies and is in compliance with relevant regulations [1][2][3]. Group 1: Internal Control and Compliance - The company received a negative internal control audit report from Zhongqin Wanxin for the year 2023, leading to a risk warning on its stock from May 6, 2024 [3][4]. - The company has implemented corrective measures, including compliance training and strengthening internal control systems to prevent fund occupation and financial misconduct [5][6]. - As of the date of the review, the company has completed the necessary rectifications and its internal controls are deemed effective, meeting the conditions to apply for the removal of the risk warning [9][10]. Group 2: Financial Performance and Audit Findings - The company reported a net profit of -365.1 million yuan for the year 2024, with a total unallocated profit of -782.8 million yuan [25][30]. - The audit report for 2024 provided by Zhongqin Wanxin indicated that the company maintained effective internal controls over financial reporting as of December 31, 2024 [14][23]. - The company has addressed previous financial misstatements from 2017 and 2019 by restating its financial reports, which aligns with the requirements set forth by the regulatory authorities [10][24]. Group 3: Regulatory Compliance and Risk Warnings - The company is currently under continued risk warnings due to the timing of the administrative penalty, which has not yet reached the twelve-month threshold for removal [25][30]. - The review confirmed that the company does not meet any conditions for mandatory delisting or additional risk warnings as per the stock listing rules [26][30]. - The company has not encountered any new circumstances that would trigger additional risk warnings, maintaining compliance with the stock exchange regulations [20][30].

Core Viewpoint - Huaxi Energy Industrial Co., Ltd. has received an audit report for its 2024 internal control that expresses an inability to provide an opinion, leading to the implementation of "other risk warnings" on its stock starting April 30, 2025 [1][2]. Group 1: Audit Report and Risk Warnings - The internal control audit for 2024 was conducted by Sichuan Huaxin (Group) Accounting Firm, which issued a report with no opinion [2]. - According to the Shenzhen Stock Exchange regulations, if a company receives an audit report with no opinion or a negative opinion regarding its internal control, it will face risk warnings on its stock trading [2]. Group 2: Company Measures and Progress - The company's board has taken the audit report seriously and assigned personnel to address the identified deficiencies, aiming to apply for the removal of the ST designation as soon as possible [2][3]. - A rectification leadership group was established on May 15, 2025, with specific responsibilities and timelines outlined for addressing the issues [3]. - The company has already completed the standardization of discrepancies between payment accounts and recorded units, and has conducted self-checks on accounts receivable and work-in-progress internal controls [3].

Core Viewpoint - The company, Guizhou BaiLing Pharmaceutical Group Co., Ltd., has faced significant challenges in its financial performance for the year 2024, with a notable decrease in revenue and a mixed picture regarding profitability and cash flow [14][22]. Financial Performance - The company reported operating revenue of 3.825 billion yuan, a decrease of 10.26% year-on-year [14]. - The net profit attributable to shareholders was 33.62 million yuan, showing an increase compared to a net loss of 82.44 million yuan in the previous year, marking an 81.33% improvement [14][22]. - The net cash flow from operating activities was 9.02 million yuan, a significant decrease of 92.83% year-on-year [14]. Revenue Breakdown - The revenue composition for 2024 included: - Traditional Chinese medicine: 3.381 billion yuan, down 12.00% - Western medicine: 293.07 million yuan, down 0.68% - Chinese medicinal materials: 22.04 million yuan, up 30.24% - Medical services: 66.68 million yuan, up 13.21% - Others: 62.56 million yuan, up 25.57% [17]. Cost and Expense Analysis - The total operating costs were 1.603 billion yuan, down 15.88% year-on-year, primarily due to decreased sales volume [18]. - Sales expenses decreased by 19.77% to 1.854 billion yuan, reflecting cost-cutting measures [18]. - The gross profit margin improved to 58.09%, up 2.80% from the previous year, attributed to lower raw material prices [19]. Internal Control and Audit Opinions - The company received a qualified audit opinion for 2023 due to significant internal control deficiencies related to sales expense recognition [5][8]. - In 2024, the company implemented corrective measures and received a clean audit opinion with an emphasis on matters, indicating improvements in internal controls [10][11]. Customer and Supplier Concentration - The top five customers accounted for 39.13% of total sales, while the top five suppliers represented 46.05% of total purchases, indicating a high concentration risk [14][28]. Market Conditions - The pharmaceutical industry faced challenges due to decreased demand for cold and flu medications, as consumers had stocked up during previous health crises [17]. - The overall market for pharmaceutical products has seen price reductions, contributing to the revenue decline [17]. Quarterly Performance Fluctuations - The company experienced significant fluctuations in quarterly performance, with the first and fourth quarters showing higher revenues due to seasonal demand for cold and flu medications [25][26]. - The cash flow from operating activities was notably negative in the first and third quarters, primarily due to delayed receivables [27]. Conclusion - The company is navigating a challenging financial landscape with a focus on improving internal controls and addressing revenue declines through strategic adjustments in operations and cost management [14][22].

Core Viewpoint - Guizhou BaiLing (ST BaiLing) has completed internal control rectification and is applying to remove the risk warning label after a year of efforts, aiming for a turnaround in its financial performance [2][6]. Internal Control and Compliance - The company has made significant improvements in its internal control and compliance systems, establishing a compliance management department and enhancing training for staff to prevent future violations [5][6]. - An audit report confirmed that ST BaiLing maintained effective internal control over financial reporting in all significant aspects [6]. Financial Performance - In 2024, ST BaiLing reported revenue of 3.825 billion yuan, a decrease of 10.26% year-on-year, while net profit attributable to shareholders was 33.62 million yuan, an increase of 108.11% [7]. - Despite appearing to turn a profit, the company's net profit after excluding non-recurring items was -82.44 million yuan, indicating ongoing financial challenges [7]. Market Challenges - The company faced declining demand for its products due to a public health event in late 2023, which led to overstocking of certain medications, resulting in reduced sales in 2024 [7][8]. - In the first quarter of 2025, revenue dropped to 761 million yuan, a decline of 42.93% year-on-year, with a significant decrease in net profit [7][8]. Accounts Receivable and Risk Management - As of the end of the first quarter of 2025, ST BaiLing's accounts receivable reached 1.843 billion yuan, a 15.51% increase from the beginning of the year [8]. - The company is actively managing credit risks by conducting assessments of customers and monitoring receivables to mitigate potential bad debt risks [8].